These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35007957)

  • 1. Safer in care: A pandemic-tested model of integrated HIV/OUD care.
    Eaton EF; Tamhane A; Turner W; Raper JL; Saag MS; Cropsey KL
    Drug Alcohol Depend; 2022 Feb; 231():109241. PubMed ID: 35007957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice.
    Pytell JD; Buresh ME; Graddy R
    Addict Sci Clin Pract; 2019 Dec; 14(1):46. PubMed ID: 31856915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
    James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
    Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Financial Model for Team-Based Opioid Use Disorder Treatment.
    Farrar M; White Z; Hulkower S; Fagan EB; Wilson CG
    J Am Board Fam Med; 2020; 33(1):124-128. PubMed ID: 31907253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV care using differentiated service delivery during the COVID-19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs.
    McGinnis KA; Skanderson M; Justice AC; Akgün KM; Tate JP; King JT; Rentsch CT; Marconi VC; Hsieh E; Ruser C; Kidwai-Khan F; Yousefzadeh R; Erdos J; Park LS
    J Int AIDS Soc; 2021 Oct; 24 Suppl 6(Suppl 6):e25810. PubMed ID: 34713585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.
    Hodgkin D; Horgan C; Bart G
    Addict Sci Clin Pract; 2021 Jul; 16(1):45. PubMed ID: 34225785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
    Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
    Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown.
    Hodges J; Waselewski M; Harrington W; Franklin T; Schorling K; Huynh J; Tabackman A; Otero K; Ingersoll K; Tiouririne NA; Flickinger T; Dillingham R
    Addict Sci Clin Pract; 2022 Mar; 17(1):16. PubMed ID: 35255965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to OUD Treatment and Maintenance of Sobriety amid the COVID-19 Pandemic.
    Rahman F; Evans N; Bernhardt J
    Subst Use Misuse; 2021; 56(7):1005-1009. PubMed ID: 33754956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: A feasibility study.
    Tofighi B; Grazioli F; Bereket S; Grossman E; Aphinyanaphongs Y; Lee JD
    Am J Addict; 2017 Sep; 26(6):581-586. PubMed ID: 28799677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
    Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
    Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 and practice transformation: Building an office-based opioid treatment program in a family medicine residency practice.
    Colistra AL; Chung YK; Harbove S; Taveras YJ; Letcher A; Biery N; Keister DM
    Fam Syst Health; 2023 Jun; 41(2):235-239. PubMed ID: 36548043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.